Table 3.

Ongoing BsAb trials in MCL (including for previously untreated patients)

SettingAgent(s)NCTGeographyNotes
R/R Epcoritamab, ibrutinib NCT05283720 Global  
R/R Epcoritamab, ibrutinib, venetoclax 
Treatment naïve Epcoritamab, ibrutinib, venetoclax 
R/R Glofitamab, lenalidomide NCT06192888 United States Prior BTKi mandatory; prior lenalidomide acceptable if >12 months interval since treatment and previously sensitive 
R/R Glofitamab, pirtobrutinib NCT05833763 Australia Prior BTKi mandatory 
NCT06252675 United States Must have responded to prior BTKi therapy 
Treatment naïve Glofitamab, ibrutinib NCT06357676 United States Either high-risk disease or ≥65 years old 
R/R Acalabrutinib, obinutuzumab, and glofitamab NCT06054776 United States Incorporates measurable residual disease testing 
Treatment naïve Glofitamab, obinutuzumab, venetoclax, and lenalidomide NCT05861050 United States At least one high-risk disease feature must be present 
R/R Glofitamab vs investigator's choice (rituximab-lenalidomide or rituximab-bendamustine) NCT06084936 Global Prior BTKi mandatory 
Mosunetuzumab NCT05207670 United States Prior BTKi mandatory 
Mosunetuzumab – polatuzumab-vedotin NCT03671018 United States, Europe ≥2 prior lines of systemic therapy including BTKi, anti-CD20 MAb, and chemotherapy 
SettingAgent(s)NCTGeographyNotes
R/R Epcoritamab, ibrutinib NCT05283720 Global  
R/R Epcoritamab, ibrutinib, venetoclax 
Treatment naïve Epcoritamab, ibrutinib, venetoclax 
R/R Glofitamab, lenalidomide NCT06192888 United States Prior BTKi mandatory; prior lenalidomide acceptable if >12 months interval since treatment and previously sensitive 
R/R Glofitamab, pirtobrutinib NCT05833763 Australia Prior BTKi mandatory 
NCT06252675 United States Must have responded to prior BTKi therapy 
Treatment naïve Glofitamab, ibrutinib NCT06357676 United States Either high-risk disease or ≥65 years old 
R/R Acalabrutinib, obinutuzumab, and glofitamab NCT06054776 United States Incorporates measurable residual disease testing 
Treatment naïve Glofitamab, obinutuzumab, venetoclax, and lenalidomide NCT05861050 United States At least one high-risk disease feature must be present 
R/R Glofitamab vs investigator's choice (rituximab-lenalidomide or rituximab-bendamustine) NCT06084936 Global Prior BTKi mandatory 
Mosunetuzumab NCT05207670 United States Prior BTKi mandatory 
Mosunetuzumab – polatuzumab-vedotin NCT03671018 United States, Europe ≥2 prior lines of systemic therapy including BTKi, anti-CD20 MAb, and chemotherapy 
[ViewLarge]
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal